Cite
APA Citation
Schuler, M., Paz-Ares, L., Sequist, L. V., Hirsh, V., Lee, K. H., Wu, Y., Lu, S., Zhou, C., Feng, J., Ellis, S. H., Samuelsen, C. H., Tang, W., Märten, A., Ehrnrooth, E., Park, K., & Yang, J. C. (2019). first-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung cancer, 133, 10–19. http://access.bl.uk/ark:/81055/vdc_100085410007.0x000053